Joseph Chen, Alessandra Bearz, Dong-Wan Kim, Hirva Mamdani, Jessica Bauman, Rita Chiari, Sai-Hong Ignatius Ou, Benjamin J Solomon, Ross A Soo, Enriqueta Felip, Alice T Shaw, Holger Thurm, Jill S Clancy, Kimberly Lee, Melissa O'Gorman, Cherie Tanski, Yazdi K Pithavala
BACKGROUND AND OBJECTIVE: Lorlatinib is a tyrosine kinase inhibitor approved for the treatment of advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. This study assessed the effect of steady-state lorlatinib on the metabolic enzymes cytochrome P450 (CYP) 2B6, CYP2C9, and uridine 5'-diphospho-glucuronosyltransferase (UGT) and the P-glycoprotein (P-gp) transporter. METHODS: Thirty-two patients received a single oral dose of a probe drug on Day - 2 to determine the pharmacokinetics of the probe drug alone...
December 11, 2023: Clinical Pharmacokinetics